Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Navigating the Complex Treatment Landscape in Relapsed/Refractory Myeloma
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 12, 2022 Expiration: October 11, 2023
Start Activity
Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics Inc.
Regeneron Pharmaceuticals, Inc.
Paul G. Richardson, MD
Program Director
Natalie S. Callander, MD
Noopur Raje, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan therapeutic strategies for patients with R/R MM based on currently available data, individual patient and disease characteristics, and response to and tolerance of prior therapy
  • Evaluate the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Mitigate treatment-related symptoms associated with new targeted therapies in patients with R/R MM
  • Identify patients with R/R MM who would be eligible for enrollment on clinical trials

Information on this Educational Activity

Disclosure and Conflict of Interest Policy

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC (CCO). Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

 

Program Director

Paul G. Richardson, MD

R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research

Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD: consultant/advisor/speaker: AstraZeneca, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Karyopharm, Novartis, Oncopeptides, Sanofi, Secura Bio, Takeda; researcher: Celgene/Bristol Myers Squibb, Karyopharm, Oncopeptides, Takeda.

Faculty

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has no relevant financial relationships to disclose.
Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: AbbVie, Amgen, Bluebird Bio, Bristol-Myers Squibb, Caribou Biosciences & Immuneel, Janssen, Pfizer, Sanofi, Takeda; researcher: Bluebird Bio.

Staff

Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen M. Rosenthal, PhD, has no relevant financial relationships to disclose.
Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant financial relationships to disclose.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.
Ramya Moorthy

Clinical Editor

Ramya Moorthy, has no relevant financial relationships to disclose.
Saranya Vijayakumar, PhD

Clinical Editor

Saranya Vijayakumar, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.
Brian Purves, PharmD, MBA
Brian Purves, PharmD: The following relationships have ended within the last 24 months: Employee of AstraZeneca with focus in Medical Information for Respiratory Inhaled-Symbicort.

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose.

Target Audience

This educational program is intended for hematologists, medical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with R/R MM

Goal

The goal of this activity is to improve the knowledge and competence of learners in selecting individualized treatments for patients with R/R MM.

Joint Accreditation Statement

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 12, 2022, through October 11, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Navigating the Complex Treatment Landscape in Relapsed/Refractory Myeloma
  • CME

Loading...
In this on-demand webcast from a live webinar, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, discuss recent advances in new and emerging therapies for patients with relapsed/refractory multiple myeloma.
Paul G. Richardson, MD
Program Director
Natalie S. Callander, MD
Noopur Raje, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 12, 2022 Expiration: October 11, 2023

Related Content

Downloadable slides on recent updates in R/R FL, with a focus on bispecific antibodies and CAR T-cell therapy, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Laurie H. Sehn, MD, MPH Released: February 2, 2023

Downloadable slides on recent updates in R/R FL, with a focus on second-line therapies and third-line epigenetic modifiers and PI3K inhibitors, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Laurie H. Sehn, MD, MPH Released: February 2, 2023

On-demand webcast from an ASH 2022 satellite symposium on BTK inhibitors for patients with CLL and MCL, from Clinical Care Options (CCO)

Jeff Sharman, MD
Program Director
Ian W. Flinn, MD, PhD Susan M. O'Brien, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 31, 2023 Expired: January 30, 2024

On-demand Clinical Care Options (CCO) webcast from a December 2022 symposium: experts discuss new care standards and evolving treatment strategies for aggressive B-cell lymphomas

John P. Leonard, MD
Program Director
John Allan, MD Laurie H. Sehn, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 30, 2023 Expired: January 29, 2024
Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics Inc.
Regeneron Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings